Minerva Neurosciences, Inc. (NERV) saw a 224.06% increase in its price changes percentage, reaching $8.62. The company's focus on central nervous system diseases and its lead product candidate, roluperidone, for schizophrenia treatment, is underscored by the FDA's requirement for a confirmatory study, as reported by Minerva.
In the financial services sector, the Tradr 1.5X Short NVDA Daily ETF (NVDS) and the Tradr 2X Short TSLA Daily ETF (TSLQ) recorded substantial gains. NVDS's price rose to $34.33, a 202.51% increase, while TSLQ's price increased to $22.94, marking a 201.45% rise. Tradr ETFs has also launched new 2X long single-stock leveraged ETFs, expanding their lineup to 23 leveraged ETFs, as highlighted by Tradr ETFs.
These top gainers span diverse industries, from healthcare to financial services, each offering unique opportunities and risks. Investors should conduct thorough research and consider the volatility and specific characteristics of these investments before making decisions.
